#1 Clinical Trials Search in Europe

Sar444656

Clinical trials are studying Sar444656 in adults with moderate to severe hidradenitis suppurativa and atopic dermatitis. These studies look at how well it works and how safe it is compared with placebo. Both trials are Phase 2 and include adult participants.

Table of Contents

Clinical trials overview

Two Phase 2 clinical trials studied Sar444656 in adults with moderate to severe skin disease.[1][2] Both were interventional studies, which means the researchers gave a study treatment and then measured outcomes over time.[1][2]

Both trials were completed and compared Sar444656 with a matched placebo, meaning a look-alike treatment without the active study drug.[1][2]

Hidradenitis suppurativa study

NCT06028230 studied adult participants with moderate to severe hidradenitis suppurativa.[1] The study title says it evaluated the efficacy and safety of Sar444656 compared with placebo.[1]

This trial enrolled 370 participants and was completed.[1] The brief summary says the main goal was to see whether Sar444656 reduced abscess and inflammatory nodule count by Week 16.[1]

Atopic dermatitis study

NCT06058156 studied adult participants with moderate to severe atopic dermatitis.[2] The trial compared Sar444656 with placebo and was also completed.[2]

This study enrolled 322 participants.[2] Its brief summary says the goal was to assess the effect of Sar444656 on AD lesions, which are the skin areas affected by the disease.[2]

What the trials measured

The main result for the hidradenitis suppurativa study was the percent change from baseline in total abscess and inflammatory nodule count.[1] Baseline means the starting point before treatment began.[1]

The main result for the atopic dermatitis study was the percent change from baseline in EASI.[2] EASI is a score used to measure how severe atopic dermatitis is.[2]

Who could take part

Both studies were limited to adult participants with moderate to severe disease.[1][2] The trial data do not describe healthy volunteers or children as target groups.[1][2]

The studies focused on people whose skin disease was serious enough to be described as moderate to severe.[1][2] This means the researchers were looking at patient groups with a meaningful disease burden.[1][2]

Key points for patients

  • Sar444656 has been studied in two completed Phase 2 trials.[1][2]

  • One trial focused on hidradenitis suppurativa, and the other focused on atopic dermatitis.[1][2]

  • Both trials compared Sar444656 with matched placebo.[1][2]

  • The main goal in both studies was to measure whether the treatment improved disease signs over time.[1][2]

  • The main study groups were adults with moderate to severe disease.[1][2]

Trial ID Phase Condition studied Status Enrollment Main endpoint
NCT06028230 Phase 2 Moderate to severe hidradenitis suppurativa Completed 370 Percent change from baseline in total abscess and inflammatory nodule count
NCT06058156 Phase 2 Moderate to severe atopic dermatitis Completed 322 Percent change from baseline in EASI

FAQ

  • What conditions is Sar444656 being studied for? Sar444656 is being studied in moderate to severe hidradenitis suppurativa and moderate to severe atopic dermatitis. These are skin conditions that can cause painful lumps, inflammation, and ongoing skin symptoms.
  • Who can join these Sar444656 trials? The trials enrolled adult participants. Both studies focused on adults with moderate to severe disease, so they were not general studies in healthy volunteers.
  • What phase are the Sar444656 studies? Both trials are Phase 2 studies. Phase 2 trials usually check whether a treatment may work and continue to monitor safety in a larger group of people.
  • What did the trials measure? One study measured the percent change in total abscess and inflammatory nodule count. The other measured the percent change in EASI, which is a score used to track atopic dermatitis severity.
  • Were these trials compared with placebo? Yes. Both studies compared Sar444656 with matched placebo. A placebo looks like the study treatment but does not contain the active study drug.

Ongoing Clinical Trials on Sar444656

  • Study on the Effectiveness and Safety of SAR444656 for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    1
    Investigated drugs:
    Germany Greece Poland Spain

  • Study on SAR444656 for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Greece Poland

Glossary

  • Atopic dermatitis: A long-lasting skin condition that causes itchy, inflamed, and irritated skin. It is also called AD.
  • Hidradenitis suppurativa: A long-term skin disease that can cause painful lumps, abscesses, and inflammation, often in body areas where skin rubs together.
  • Moderate to severe: A description of disease seriousness. It means the condition is not mild and may cause a larger effect on daily life.
  • Phase 2: A stage of clinical research that looks more closely at whether a treatment may work and continues to check safety.
  • Placebo: A treatment that looks like the study drug but has no active medicine. It helps researchers compare results fairly.
  • Efficacy: How well a treatment works for the condition being studied.
  • Safety: How well a treatment is tolerated and whether it causes unwanted problems.
  • Enrollment: The number of participants who joined a clinical trial.
  • Abscess: A painful pocket of pus under the skin.
  • Inflammatory nodule: A firm, swollen lump caused by inflammation.
  • EASI: A score used by researchers to measure how severe atopic dermatitis is.

References